FLUNIXIN- flunixin meglumine injection, solution

Quốc gia: Hoa Kỳ

Ngôn ngữ: Tiếng Anh

Nguồn: NLM (National Library of Medicine)

Thành phần hoạt chất:

Flunixin Meglumine (UNII: 8Y3JK0JW3U) (Flunixin - UNII:356IB1O400)

Sẵn có từ:

VetTek

INN (Tên quốc tế):

Flunixin Meglumine

Thành phần:

Flunixin Meglumine 50 mg in 1 mL

Tuyến hành chính:

INTRAMUSCULAR

Loại thuốc theo toa:

PRESCRIPTION

Chỉ dẫn điều trị:

INDICATIONS Horse: Flunixin Injection (flunixin meglumine injection) is recommended for the alleviation of inflammation and pain associated with musculoskeletal disorders in the horse. It is also recommended for the alleviation of visceral pain associated with colic in the horse. Cattle: Flunixin Injection (flunixin meglumine injection) is indicated for the control of pyrexia associated with bovine respiratory disease, endotoxemia and acute bovine mastitis. Flunixin Injection is also indicated for the control of inflammation in endotoxemia. CONTRAINDICATIONS Horse: There are no known contraindications to this drug when used as directed. Intra-arterial injection should be avoided. Horses inadvertently injected intra-arterially can show adverse reactions. Signs can be ataxia, incoordination, hyperventilation, hysteria, and muscle weakness. Signs are transient and disappear without antidotal medication within a few minutes. Do not use in horses showing hypersensitivity to flunixin meglumine. Cattle : NSAIDS inhibit production of prostaglandins which are important in signaling the initiation of parturition. The use of flunixin can delay parturition and prolong labor which may increase the risk of still birth. Do not use Flunixin Injection (flunixin meglumine injection) within 48 hours of expected parturition. Do not use in animals showing hypersensitivity to flunixin meglumine. Use judiciously when renal impairment or gastric ulceration are suspected.

Tóm tắt sản phẩm:

HOW SUPPLIED Flunixin Injection (flunixin meglumine injection), 50 mg/mL, is available in 250 mL multi-dose vials.

Tình trạng ủy quyền:

Abbreviated New Animal Drug Application

Đặc tính sản phẩm

FLUNIXIN- FLUNIXIN MEGLUMINE INJECTION, SOLUTION
VETTEK
----------
FLUNIXIN INJECTION
(FLUNIXIN MEGLUMINE INJECTION)
50 MG/ML
Only for Intravenous Use in Beef and Dairy Cattle. Not for Use in Dry
Dairy Cows and
Veal Calves. For Intravenous and Intramuscular Use in Horses.
CAUTION
Federal law restricts this drug to use by or on the order of a
licensed veterinarian.
DESCRIPTION
Each milliliter of Flunixin Injection (flunxin meglumine injection)
contains 50 mg flunixin
equivalent to 83 mg flunixin meglumine), 0.1 mg edetate disodium, 2.2
mg sodium
formaldehyde sulfoxylate, 4.0 mg diethanolamine, 207.2 mg propylene
glycol, 5.0 mg
phenol as preservative, hydrochloric acid, water for injection q.s.
PHARMACOLOGY
Flunixin meglumine is a potent, non-narcotic, nonsteroidal, analgesic
agent with anti-
inflammatory and antipyretic activity. It is significantly more potent
that pentazocine,
meperidine, and codeine as an analgesic in the rat yeast paw test.
_Horse:_ Flunixin is four times as potent on a mg-per-mg basis as
phenylbutazone as
measured by the reduction in lameness and swelling in the horse.
Plasma half-life in
horse serum is 1.6 hours following a single dose of 1.1 mg/kg.
Measurable amounts are
detectable in horse plasma at 8 hours postinjection.
_Cattle:_ Flunixin meglumine is a weak acid (pKa=5.82) which exhibits
a high degree of
plasma protein binding (approximately 99%).
However, free (unbound) drug appears to
readily partition into body tissues (V
predictions range from 297 to 782 mL/kg.
Total
body water is approximately equal to 570 mL/kg).
In cattle, elimination occurs primarily
through biliary excretion.
This may, at least in part, explain the presence of multiple
peaks in the blood concentration/time profile following IV
administration.
In healthy cattle, total body clearance has been reported to range
from 90 to 151
mL/kg/hr.
These studies also report a large discrepancy between the volume of
distribution at steady state (V
) and the volume of distribution associated with the
terminal elimination phase (